The history of Sildenafil presents a challenging picture for shareholders. While the initial launch generated substantial returns, the end of its patent opened the door to cheaper competitors, dramatically diminishing https://socialwebleads.com/story7174984/sildenafil-and-pharma-a-risky-opportunity